November 28, 2014
Otsuka Pharmaceutical Co., Ltd.
L-Cartin® FF Tablets For Carnitine Deficiencies To Be Introduced in Japan on December 5
Active Ingredient Carnitine in Free Form (FF*) to Address the Needs of Medical Field
- L-Cartin® FF tablets were developed with the same active ingredient levocarnatine (free form) as the oral solution and injectable, mindful of the need in medical settings to conveniently convert patient dosing across the different forms.
- Carnitine deficiency can occur among people, for example, with congenital metabolic disorders or who are undergoing hemodialysis and symptoms include muscle pain, fatigue, hyperammonemia (elevated ammonia levels in blood) or hypoglycemic coma in severe cases, and a therapy is needed in these cases.
- Otsuka Pharmaceutical introduced L-Cartin tablets in 1990 and only Otsuka markets a treatment for carnitine deficiency in Japan.
On December 5 Otsuka Pharmaceutical is launching a new form of L-Cartin, L-Cartin Free Form (FF) tablets (generic name levocarnatine) in two doses, 100mg and 250mg. This follows regulatory approval in Japan on June 26 for the manufacture and sale of L-Cartin FF tablets for carnitine deficiency.
- *FF (free-form) levocarnatine is the unchlorinated form of levocarnatine.
Information in this news release was current as of the original release date.